⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320780 | 0.76 | PGR (0.42) | — | |
| SCHEMBL30104097 | 0.76 | PGR (0.44) | — | |
| SCHEMBL346857 | 0.72 | — | — | |
| SCHEMBL23006 | 0.72 | — | — | |
| SCHEMBL30541257 | 0.71 | ESR1 (0.42) | — | |
| SCHEMBL9050923 | 0.71 | L3MBTL1 (0.41) | — | |
| SCHEMBL18830906 | 0.70 | — | — | |
| SCHEMBL1363558 | 0.70 | — | — | |
| SCHEMBL8222639 | 0.70 | — | — | |
| SCHEMBL5211654 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-11718607-B2 | Atypical coupling method for the preparation of 1,2-di(thiophen-2-yl)ethene-1,2-diol compounds via a Cu(II) catalyst | QATAR UNIVERSITY (QA) | 2023-08-08 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20220204487-A1 | ATYPICAL COUPLING METHOD FOR THE PREPARATION OF 1,2-DI(THIOPHEN-2-YL)ETHENE-1,2-DIOL COMPOUNDS VIA A CU(II) CATALYST | QATAR UNIVERSITY (QA) | 2022-06-30 | — | — | US | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113286784-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019041047-A1 | FLUORINATED DITHIENYL-DIKETOPYRROLOPYRROLE MONOMERS AND POLYMERS AND USES THEREOF | UNIVERSITé LAVAL (CA) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019041047-A1 | FLUORINATED DITHIENYL-DIKETOPYRROLOPYRROLE MONOMERS AND POLYMERS AND USES THEREOF | UNIVERSITé LAVAL (CA) | 2019-03-07 | — | — | WO | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1275630-A1 | PROCESS FOR PRODUCING SUBSTITUTED AROMATIC COMPOUND | Mitsui Chemicals, Inc. (JP) | 2003-01-15 | — | — | EP | disclosed |
| CN-1380880-A | Process for producing substituted aromatic compound | MITSUI CHEMICALS INC (JP) | 2002-11-20 | — | — | CN | disclosed |
| US-20020161227-A1 | PROCESS FOR PREPARATION OF SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2002-10-31 | — | — | US | disclosed |
| US-6469224-B1 | REACTING A PHOSPHAZENIUM COMPOUND WITH A HALOGENATED AROMATIC COMPOUNDS, ESPECIALLY CHLORINATED AROMATIC COMPOUNDS | MITSUI CHEMICALS, INC. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-4695634-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1987-09-22 | — | — | US | disclosed |
| US-4622406-A | CHEMICAL INTERMEDIATES, TRIMETHYLSILOXY COMPOUNDS | PFIZER INC. (US) | 1986-11-11 | — | — | US | disclosed |
| US-4562267-A | Intermediates of hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1985-12-31 | — | — | US | disclosed |
| US-4423233-A | ALPHA-HYDROXY CARBOXIMIDATE INTERMEDIATES | PFIZER INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4381308-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-04-26 | — | — | US | disclosed |
| US-4332952-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-06-01 | — | — | US | disclosed |